Wedbush Reaffirms Outperform Rating for Immunome (NASDAQ:IMNM)

Wedbush reissued their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research report report published on Monday,RTT News reports. They currently have a $33.00 price target on the stock.

Separately, Piper Sandler dropped their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $27.17.

Immunome Trading Up 5.5 %

Shares of NASDAQ IMNM opened at $9.21 on Monday. The company has a 50-day moving average of $10.06 and a two-hundred day moving average of $11.87. Immunome has a 1-year low of $8.39 and a 1-year high of $26.70. The company has a market cap of $734.75 million, a PE ratio of -1.14 and a beta of 1.93.

Insider Buying and Selling at Immunome

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. This represents a 28.87 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

A number of large investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Immunome by 32.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,193 shares of the company’s stock valued at $618,000 after purchasing an additional 14,328 shares in the last quarter. Woodline Partners LP increased its position in Immunome by 6.1% during the fourth quarter. Woodline Partners LP now owns 980,925 shares of the company’s stock worth $10,417,000 after buying an additional 56,533 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in Immunome during the 4th quarter valued at $512,000. Two Sigma Investments LP acquired a new position in Immunome in the 4th quarter valued at about $1,640,000. Finally, Point72 Asset Management L.P. boosted its stake in Immunome by 46.3% in the 4th quarter. Point72 Asset Management L.P. now owns 688,790 shares of the company’s stock valued at $7,315,000 after purchasing an additional 218,143 shares during the period. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.